GW501516 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-10-02 and is reviewed periodically as new material appears.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
| Property | Value | Notes |
|---|---|---|
| Chemical class | PPARδ agonist | Not an anabolic steroid. |
| Common synonyms | GW501516, GW-1516 | Cardarine is an informal name. |
| Appearance | White to off-white powder | Typical for research-grade solid. |
| Solubility class | Poorly soluble in water; soluble in some organic solvents | Such as DMSO or ethanol in laboratory settings. |
| Typical storage temperature | Cool, dry, protected from light | Specific conditions vary by supplier and form. |
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
GW501516 acts as a selective agonist at PPARδ, a nuclear receptor that regulates transcription of genes involved in lipid handling and energy metabolism. Activation of PPARδ in preclinical models increases fatty acid oxidation, mitochondrial biogenesis, and exercise endurance in rodents. These effects have made the compound a subject of metabolic research and also a target for sport anti-doping rules. In humans, however, controlled studies are limited, and whether similar endurance or metabolic changes occur at tolerated exposures remains an open question. The receptor’s broad tissue distribution also means downstream effects may vary by organ and condition.
Detection of GW501516 in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. Urine is a common matrix in anti-doping analysis, while blood or plasma may be used in research settings. Sample preparation can involve enzymatic hydrolysis, protein precipitation, or solid-phase extraction before instrumental analysis. Because the compound undergoes metabolism, assays may target the parent molecule, one or more metabolites, or both. Detection windows are not fixed; they depend on factors such as dose, route, individual metabolism, and assay sensitivity. Reference standards are required for accurate identification and quantification.
Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.
Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.
Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.
Artesunate is a medication used to treat malaria. The intravenous form is preferred to quinine for severe malaria. Often it is used as part of combination therapy, such as artesunate plus mefloquine. It is not used for the prevention of malaria. Artesunate can be given by injection into a vein, injection into a muscle, by mouth, and by rectum. The most common side effects include kidney failure requiring dialysis, hemoglobinuria (the presence of hemoglobin in urine) and jaundice. Artesunate is generally well tolerated. Side effects may include a slow heartbeat, allergic reaction, dizziness, and low white blood cell levels. During pregnancy it appears to be a safer option, even though animal studies have found harm to the baby. Use is likely fine during breastfeeding. It is in the artemisinin class of medication. Artesunate was developed by Liu Xu in 1977. It is on the World Health Organization's List of Essential Medicines. It was approved for medical use in the United States in May 2020. It is in the class of medications known as artemisinins, which are derivatives from "qinghao", or sweet wormwood plant (Artemisia annua).
== Structure == The inactive form of Limulus clotting enzyme, referred to as proclotting enzyme, consists of a single chain glycoprotein. The enzyme is activated upon cleavage at the Arg98-Ile99 bond by Limulus clotting factor B or Limulus clotting factor G. The active clotting enzyme consists of a light and heavy chain linked together by a disulfide bridge. The active site of the clotting enzyme is located in the heavy chain and contains the His-Asp-Ser catalytic triad that is common among serine proteases. The sequence of the heavy chain in the serine protease region is 34.1% homologous to that of human clotting factor X, and four disulfide linkages are found in the same locations in both enzymes (and in prothrombin). These similarities indicate a relationship between serine protease structure and function. Limulus clotting enzyme also has substrate specificity similar to mammalian factor X. The crystal structure of the enzyme is unknown. The enzyme’s light chain contains a clip-like disulfide-knotted structure. Sequence homology in this region to the precursor of serine protease easter in Drosophila suggests that this structure may be common in invertebrate serine protease zymogens. Structural similarity of the light chain clip domain to horseshoe crab defensin suggests that the clip domain may have some antimicrobial activity. The amino acid sequences of Limulus clotting enzyme and Limulus clotting factor B are 35.9% similar.
7-Eleven, Inc. is an American convenience store chain headquartered in Irving, Texas. It is a wholly owned subsidiary of Seven-Eleven Japan, which is owned by Seven & I Holdings, a Japanese retail holding company. The chain was founded in 1927 as the Southland Ice Company, operating an ice house storefront in Dallas. Owned by the Southland Corporation, the chain expanded its convenience stores and renamed them Tote'm Stores between 1928 and 1946. The Southland Corporation changed the stores' name to 7-Eleven in 1946 to reflect their expanded hours of operation (7 a.m. to 11 p.m.). The Southland Corporation started franchising its stores in 1961. In 1973, Ito-Yokado, a Japanese supermarket chain, signed a franchise agreement with the Southland Corporation to develop 7-Eleven convenience stores in Japan. Later in 1991, operating the Japanese stores under Seven-Eleven Japan, Ito-Yokado acquired a 70% stake in the Southland Corporation. As the majority owner, it changed the Southland Corporation's name to 7-Eleven, Inc. Ito-Yokado expanded to 100% ownership in November 2005, making 7-Eleven, Inc. a wholly owned subsidiary of Seven-Eleven Japan. That same year, Ito-Yokado reorganized its collective businesses into the holding company Seven & I Holdings, with 7-Eleven, Inc. remaining wholly held by Seven-Eleven Japan. 7-Eleven operates, franchises, and licenses roughly 85,000 stores in 20 countries and territories as of August 2024. Its stores operate under its namesake brand globally.
As a result, the USSR was transformed from a largely agrarian economy into a great industrial power, leading the way for its emergence as a superpower after World War II. The war caused extensive devastation of the Soviet economy and infrastructure, which required massive reconstruction.
== Selected publications == Viswanathan, V.; Mirshad, R. (2023), "Role of Technology for wound Care in Diabetic Foot", Chronic Wound Management, Cham: Springer International Publishing, pp. 67–76, doi:10.1007/978-3-031-26110-7_4, ISBN 978-3-031-26109-1 Viswanathan, Vijay; Ahmed Khan, Balkhiwala; Nachimuthu, Sukanya; Kumpatla, Satyavani (2023). "Precision of Michigan Neuropathy Screening Instrument (MNSI) Tool for the Diagnosis of Diabetic Peripheral Neuropathy Among People with Type 2 Diabetes—A Study from South India". The International Journal of Lower Extremity Wounds. doi:10.1177/15347346231163209. ISSN 1534-7346. "Current and future perspective in the management of diabetes". {{cite journal}}: Cite journal requires |journal= (help) "Type 2 Diabetes Mellitus – The Epidemic Of The 21st Century: The Indian Scenario A Ramachandran, C Snehalatha*, Int. J. Diab. Dev. Countries (1999), Vol. 19". {{cite journal}}: Cite journal requires |journal= (help) High Prevalence of Obstructive Sleep Apnea among People with Type 2 Diabetes Mellitus in a Tertiary Care Center. J Assoc Physicians India. 2017 Nov;65(11):38-42. PMID 29322708. Need for education on footcare in diabetic patients in India. J Assoc Physicians India. 1999 Nov;47(11):1083-5. PMID 10862318. Diabetic nephropathy in type 2 diabetes: the Indian experience. J Assoc Physicians India. 2001 Dec;49:1185-7. PMID 11996441. Prevalence of pathogens in diabetic foot infection in South Indian type 2 diabetic patients. J Assoc Physicians India. 2002 Aug;50:1013-6. PMID 12421021.
Sources: en.wikipedia.org
== Evolution == NADP-malic enzyme, as all other C4 decarboxylases, did not evolve de novo for CO2 pooling to aid RuBisCO. Rather, NADP-ME was directly transformed from a C3 species in photosynthesis, and even earlier origins from an ancient cystolic ancestor. In the cytosol, the enzyme existed as a series of housekeeping isoforms purposed towards a variety of functions including malate level maintenance during hypoxia, microspore separation, and pathogen defense. In regards to the mechanism of evolution, the C4 functionality is thought to have stemmed from gene duplication error both within promoter regions, triggering overexpression in bundle-sheath cells, and within the coding region, generating neofunctionalization. Selection for CO2 preservation function as well as enhanced water and nitrogen utilization under stressed conditions was then shaped by natural pressures.
=== Archaeology in Neuchâtel during the 19th and 20th century === During the second half of the 19th century, many lake dwellings were found on the banks of lakes Neuchâtel, Bienne and Morat during a period dubbed "lake dwellings fever" (fièvre lacustre in french). The Jura waters correction lowered lake Neuchâtel height by 2.7 m which resulted in dozens of lake dwellings sites exiting from the waters. This made access to the artifacts far easier. Later, the construction of the A5 motorway (from Yverdon-les-Bains to Solothurn) alongside the north bank of Lake Neuchâtel led to the discovery of about 500'000 artifacts, many of them got included into the museum's collections.
=== Molecular biology laboratories === Polyacrylamide is also often used in molecular biology applications as a medium for electrophoresis of proteins and nucleic acids in a technique known as PAGE. PAGE was first used in a laboratory setting in the early 1950s. In 1959, the groups of Davis and Ornstein and of Raymond and Weintraub independently published on the use of polyacrylamide gel electrophoresis to separate charged molecules. The technique is widely accepted today, and remains a common protocol in molecular biology labs. Acrylamide has other uses in molecular biology laboratories, including the use of linear polyacrylamide (LPA) as a carrier, which aids in the precipitation of small amounts of nucleic acids (DNA and RNA). Many laboratory supply companies sell LPA for this use. In addition, under certain conditions, it can be used to selectively precipitate only RNA species from a mixture of nucleic acids.
The latter programme took place in Vichy, and was spread over three weeks, allowing Wenger to be able to put Frantz's teachings of isometrics into practice. In 1981, he received his manager's diploma in Paris.
Sources: en.wikipedia.org
Cardarine is commonly known as GW501516 or GW-1516. These names refer to the same synthetic compound. It is not a brand-name approved medicine.
No, cardarine is not a steroid. It is classified as a PPARδ agonist. Its structure and receptor target differ from anabolic steroids.
No regulatory agency has approved cardarine as a medicine. It was investigated in early research but development was discontinued. It is not available as a prescription drug.
It binds to and activates PPAR delta, a nuclear receptor that controls expression of genes related to fatty acid oxidation. This mechanism can alter energy metabolism in animal models. It is not a direct stimulant or fat-burning enzyme.